Quentin Kimana

Quentin Kimana

Auto-generated profile, based on publicly available information

Quentin Kimana

The University of Texas MD Anderson Cancer Center 4 Department of Gastrointestinal Medical Oncology Houston, Texas

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
XWXin Wang
Xin Wang
JHJaime Ivan Haro-Silerio
Jaime Ivan Haro-Silerio
FBFelix E.G. Beaudry
Felix E.G. Beaudry
ABAyelet Borgida
Ayelet Borgida
FAFarnoosh Abbas-Aghababazadeh
Farnoosh Abbas-Aghababazadeh
RGRobert C. Grant
Robert C. Grant
Purpose: Biliary tract cancer (BTC) is the leading cause of death in patients with primary sclerosing cholangitis (PSC). PSC-related BTC is poorly understood, and the risks and benefits of conventional and immunotherapy treatments are unknown. We aimed to characterize clinical outcomes and genomes of PSC-related BTCs. Experimental Design: This was a retrospective cohort study of patients with BTC with underlying PSC treated at MD Anderson Cancer Center (N = 46) and Princess Margaret Cancer Centre (N = 16), which were contrasted to patients with non–PSC-related BTC (N = 146). We compared outcomes between PSC and non-PSC, and PSC treated with and without immunotherapy. A combination of targeted sequencing (N = 139), whole-genome sequencing (WGS; N = 27), and WGS with paired RNA sequencing (N = 33) delineated the genomic and transcriptomic landscape of PSC-associated BTCs. Results: In PSC-related BTC, the addition of immunotherapy to chemotherapy was associated with improved first-line progression-free survival (PFS; N = 22 vs. 11; median PFS, 12.2 vs. 4.7 months; P = 0.01). Immune-related adverse events were rare (N = 2, 12.5%) and improved after treatment discontinuation. Classic actionable genomic alterations, including IDH1 mutations and FGFR2 fusions, were absent in PSC-related BTCs. PSC tumors had a 2.6-fold higher tumor mutational burden (P = 3.28e−05) compared with non-PSC tumors. Transcriptomic profiling revealed a subset of PSC tumors displaying RNA signatures of immunotherapy response. Conclusions: Immunotherapy in PSC-associated BTCs seemed safe, with a potential signal of effectiveness. Given the sample size and retrospective design, these results are hypothesis-generating. Together, these results demonstrate the unique biology underlying PSC-associated BTCs, highlighting the need for prospective trials and the development of specialized treatment strategies.

2 November 2026
Verified
Other
Open access
NSNakul M. Shah
Nakul M. Shah
BABeatriz Alvarado-Hernandez
Beatriz Alvarado-Hernandez
XCXinyue Chen
Xinyue Chen
QKQuentin Kimana
Quentin Kimana
FNFelicity Namayanja
Felicity Namayanja
SSSachet A. Shukla
Sachet A. Shukla
Supplementary Tables1 from Proteogenomic Profiling Identifies FGFR2b as a Prevalent Cell Surface Target in Intrahepatic Cholangiocarcinoma

18 August 2026 in Clinical Cancer Research
Verified
Journal Article
Closed access
NSNakul M. Shah
Nakul M. Shah
BABeatriz Alvarado-Hernandez
Beatriz Alvarado-Hernandez
XCXinyue Chen
Xinyue Chen
QKQuentin Kimana
Quentin Kimana
FNFelicity Namayanja
Felicity Namayanja
SSSachet A. Shukla
Sachet A. Shukla
Purpose: Intrahepatic cholangiocarcinoma (iCCA) is increasing in incidence and is associated with limited treatment options and poor prognosis, particularly in advanced disease. Recently, biologic strategies such as antibody–drug conjugates have expanded therapeutic opportunities across many tumor types, including HER2/neu-altered iCCA. However, validated and prevalent cell surface targets suitable for biologic therapies remain uncommon in iCCA, representing a critical bottleneck to the development of novel targeted treatments. In particular, gene-level analyses overlook tumor-enriched protein isoforms produced through alternative splicing. Experimental Design: To address this gap, we applied a novel isoform-resolved proteogenomic approach comprising transcriptomics, in silico translation, and cell surfaceomics to identify prevalent cell surface targets in iCCA and further assessed their specificity through analysis of expression data from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression datasets. Results: This approach identified a unique peptide corresponding to fibroblast growth factor receptor 2b (FGFR2b), a splicing isoform of FGFR2, that demonstrated markedly higher tumor enrichment than the alternative FGFR2 isoform, FGFR2c. FGFR2b was the predominant FGFR2 isoform in biliary tract cancer, including iCCA, in both our institutional cohort (88.6%) and TCGA (88.2%). FGFR2 fusions, in particular, were associated with high FGFR2b expression. High FGFR2b expression was associated with improved surgical outcomes, epithelial differentiation, and reduced CD8+ T-cell infiltration. Orthogonal validation using IHC in a subset of 20 patients with available tissue samples confirmed membrane-bound FGFR2b expression in 31.6% of iCCA cases, including all patients with FGFR2 fusions. Conclusions: Our findings identify FGFR2b as a prevalent and compelling therapeutic target in iCCA and provide a strong rationale for ongoing and future FGFR2b-targeted clinical trials.


28 October 2026 in ESMO Gastrointestinal Oncology
Verified
Journal Article
Open access
HYH. Yoon
H. Yoon
HJH. Jeong
H. Jeong
KKK.P. Kim
K.P. Kim
IPI. Park
I. Park
TST.J. Song
T.J. Song
CYC. Yoo
C. Yoo